Ve­rastem On­col­o­gy se­cures col­lab­o­ra­tion with Gen­Fleet Ther­a­peu­tics, po­ten­tial­ly worth up to $600M+

Ve­rastem On­col­o­gy inked a deal po­ten­tial­ly worth up to $625.5 mil­lion with Chi­nese biotech Gen­Fleet Ther­a­peu­tics that aims to move three on­col­o­gy pro­grams in­to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER